Counselors in Waterloo, NE Accepting Medicare
3 Counselors found. Showing 1 - 3
 Mr. Carl F Dorner Iii, PLMHP Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 23506 F St # 5, Waterloo, NE 68069 Phone: 402-707-5589 |
 Cynthia S Meier, LMHP Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 201 3rd Street, Waterloo, NE 68069 Phone: 402-490-5048 |
Lezli Mantzaris, LMHP, LPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1314 S 258th St, Waterloo, NE 68069 Phone: 402-881-7557 |
News Archive
Abbott's sNDA for new six-month 45-mg formulation of Lupron Depot: FDA accepts for review
The U.S. Food and Drug Administration has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron® Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer. Palliative treatment helps to relieve symptoms associated with advanced prostate cancer.
New chemical probe could tag cells for detection by MRI
The need to non-invasively "see" and track cells in living persons is indisputable - a boon to both research and development of future therapies. Emerging treatments using stem cells and immune cells are poised to most benefit from cell tracking, which would visualize their behavior in the body after delivery. Clinicians require such data to speed these cell treatments to patients.
Study identifies ten potentially modifiable risk factors for stroke
Hypertension remains the single most important modifiable risk factor for stroke, and the impact of hypertension and nine other risk factors together account for 90% of all strokes, according to an analysis of nearly 27000 people from every continent in the world, published in The Lancet.
Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement
Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.
Study focuses on addressing gaps in understanding of women's sexual pleasure
Faculty members from the Indiana University School of Public Health-Bloomington and the school's Center for Sexual Health Promotion recently published a paper in the Journal of Sex & Marital Therapy focused on addressing gaps in scientific understanding of women's sexual pleasure.
› Verified 6 days ago